Cite
HARVARD Citation
Tabernero, J. et al. (n.d.). Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet oncology. 16 (5), pp. 499-508. [Online].